These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32981127)

  • 1. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ;
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
    Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
    Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type.
    Kanis SL; de Lima-Karagiannis A; van der Ent C; Rizopoulos D; van der Woude CJ
    J Crohns Colitis; 2018 Jul; 12(8):939-947. PubMed ID: 29771301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
    Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
    Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
    Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
    Mahadevan U; Wolf DC; Dubinsky M; Cortot A; Lee SD; Siegel CA; Ullman T; Glover S; Valentine JF; Rubin DT; Miller J; Abreu MT
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):286-92; quiz e24. PubMed ID: 23200982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
    Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the Pharmacokinetic Model for Anti-TNFα Clearance in Infants Exposed to Anti-TNFα During Pregnancy.
    Wieringa JW; Kruizinga MD; Driessen GJA; van der Woude CJ; Julsgaard M
    J Crohns Colitis; 2024 Apr; 18(4):506-515. PubMed ID: 37823516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.
    Grišić AM; Dorn-Rasmussen M; Ungar B; Brynskov J; Ilvemark JFKF; Bolstad N; Warren DJ; Ainsworth MA; Huisinga W; Ben-Horin S; Kloft C; Steenholdt C
    United European Gastroenterol J; 2021 Feb; 9(1):91-101. PubMed ID: 33079627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.
    Battat R; Lukin D; Scherl EJ; Pola S; Kumar A; Okada L; Yang L; Jain A; Siegel CA
    Inflamm Bowel Dis; 2021 Aug; 27(9):1443-1451. PubMed ID: 33252119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.
    Beaulieu DB; Ananthakrishnan AN; Martin C; Cohen RD; Kane SV; Mahadevan U
    Clin Gastroenterol Hepatol; 2018 Jan; 16(1):99-105. PubMed ID: 28870657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B Vaccination Effective in Children Exposed to Anti-Tumour Necrosis Factor Alpha in Utero.
    de Lima A; Kanis SL; Escher JC; van der Woude CJ
    J Crohns Colitis; 2018 Jul; 12(8):948-953. PubMed ID: 29726943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany: Retrospective Analysis of a Large Prescription Database.
    Helwig U; Kostev K; Schmidt C
    J Clin Gastroenterol; 2021 Jan; 55(1):e1-e7. PubMed ID: 32011403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab.
    Moens A; van Hoeve K; Humblet E; Rahier JF; Bossuyt P; Dewit S; Franchimont D; Macken E; Nijs J; Posen A; Strubbe B; Van Hootegem A; Van Moerkercke W; Vermeire S; Ferrante M;
    J Crohns Colitis; 2019 Jan; 13(1):12-18. PubMed ID: 30281093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany.
    Helwig U; Braegger F; Kostev K; Schmidt C
    Dig Dis; 2020; 38(6):466-473. PubMed ID: 32045927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
    Chanchlani N; Lin S; Chee D; Hamilton B; Nice R; Arkir Z; Bewshea C; Cipriano B; Derikx LAAP; Dunlop A; Greathead L; Griffiths RL; Ibraheim H; Kelleher P; Kok KB; Lees CW; MacDonald J; Sebastian S; Smith PJ; McDonald TJ; Irving PM; Powell N; Kennedy NA; Goodhand JR; Ahmad T
    J Crohns Colitis; 2022 Mar; 16(3):389-397. PubMed ID: 34473254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.
    de Lima A; Zelinkova Z; van der Ent C; Steegers EA; van der Woude CJ
    Gut; 2016 Aug; 65(8):1261-8. PubMed ID: 25966992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.
    Liu Z; Julsgaard M; Zhu X; Martin J; Barclay ML; Cranswick N; Gibson PR; Gearry RB; van der Giessen J; Connor SJ; Rosella O; Grosen A; Toong C; Flanagan E; Wieringa JW; Janneke van der Woude C; Bell SJ;
    J Crohns Colitis; 2022 Dec; 16(12):1835-1844. PubMed ID: 35779236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.